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Abstract
Background Minimal change disease (MCD) and focal seg-
mental glomerulosclerosis (FSGS) are the most common
causes of idiopathic nephrotic syndrome (INS). We have
evaluated the reliability of urinary neutrophil-gelatinase-
associated lipocalin (uNGAL), urinary alpha1-microglobulin
(uα1M) and urinary N-acetyl-beta-D-glucosaminidase
(uβNAG) as markers for differentiating MCD from FSGS.
We have also evaluated whether these proteins are associated
to INS relapses or to glomerular filtration rate (GFR).
Methods The patient cohort comprised 35 children with
MCD and nine with FSGS; 19 healthy age-matched children
were included in the study as controls. Of the 35 patients, 28
were in remission (21 MCD, 7 FSGS) and 16 were in relapse
(14 MCD, 2 FSGS). The prognostic accuracies of these
proteins were assessed by receiver operating characteristic
(ROC) curve analyses.
Results The level of uNGAL, indexed or not to urinary
creatinine (uCreat), was significantly different between chil-
dren with INS and healthy children (p=0.02), between
healthy children and those with FSGS (p=0.007) and be-
tween children with MCD and those with FSGS (p=0.01). It
was not significantly correlated to proteinuria or GFR levels.
The ROC curve analysis showed that a cut-off value of
17 ng/mg for the uNGAL/uCreat ratio could be used to
distinguish MCD from FSGS with a sensitivity of 0.77 and
specificity of 0.78. uβNAG was not significantly different in
patients with MCD and those with FSGS (p=0.86). Only
uα1M, indexed or not to uCreat, was significantly (p<0.001)
higher for patients in relapse compared to those in remission.
Conclusions Our results indicate that in our patient cohort
uNGAL was a reliable biomarker for differentiating MCD
from FSGS independently of proteinuria or GFR levels.
Keywords Urinary NGAL . Low-molecular-weight
proteins . Idiopathic nephrotic syndrome .Minimal change
disease . Focal segmental glomerulosclerosis
Introduction
Idiopathic nephrotic syndrome (INS) remains the most fre-
quent glomerular disease in children [1] with reported inci-
dences of two to seven cases per 100,000 children [2]. It is
caused by various entities that differ in their histopatholog-
ical forms and clinical course [3]. Minimal change disease
(MCD) and focal segmental glomerulosclerosis (FSGS) are
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the most common causes of INS, representing 80 and 20 %
of the cases, respectively [3]. The pathogenesis of this dis-
ease is still unknown, and its clinical outcomes are deter-
mined by their histopathological diagnosis and responsive-
ness to steroid treatment. Steroid-sensitive INS (SSINS) is
due to MCD in 80 % of cases and has a favorable long-term
prognosis [3], while steroid-resistant INS (SRINS) is mostly
due to FSGS and is significantly associated with poor out-
comes [4, 5]. INS can be associated with various proximal
tubular dysfunctions, such as glycosuria, aminoaciduria and
bicarbonate losses [6]. The results from a few studies have
suggested that some low-molecular-weight proteins
(LMWPs), such as urinary beta2-microglobulinuria (β2M)
[6, 7] or urinary retinol binding protein (RBP) [6], can
predict steroid treatment responsiveness in INS. However,
other studies have failed to prove a significant difference in
the urinary excretion of β2M between SRINS and SSNS
patients [8]. More recently, Bennett et al. [1] reported that
urinary neutrophil gelatinase-associated lipocalin (uNGAL),
which is a small protein belonging to the lipocalin superfam-
ily, can be used to distinguish SSINS from SRINS. However,
the literature regarding the use of this novel urinary marker in
INS is limited to this one publication [1], and to date no
studies evaluating the role of uNGAL in MCD and FSGS
patients have been published.
The primary aim of our study was to evaluate the role of
three urinary LMWPs, namely, uNGAL, urinary alpha 1-
microglobulin (uα1M) and urinary N-Acetyl-beta-D-
glucosaminidase (uβNAG) in differentiating MCD from
FSGS and to discuss the underlying pathophysiological mech-
anisms. A second aim was to evaluate whether these renal
tubular proteinuria can be associated to INS relapses or to
INS glomerular filtration rate (GFR) levels.
Materials and methods
Study population
This is a prospective cross-sectional study which received
the approval of the local research ethics board; informed
consent was obtained from all participants and/or their legal
guardians. Forty-seven patients aged between 2 and 18 years,
all diagnosed with INS, and 19 healthy age-matched con-
trols, were included. Renal biopsy was performed in 44
patients with INS at the time of diagnosis for SRINS or
steroid-dependent INS, or after three or more relapses in 1
year for frequent relapsers. Of the 47 patients with INS, three
did not have a renal biopsy and were excluded from our
study. The final study population (n=44) were divided into
three groups, with group 1 (n=35, 35 biopsied) including
patients with MCD, group 2 (n=9, 9 biopsied) including
patients with FSGS and group 3 (n=19) including healthy
control children. The median time with the interquartile
range (IQR; 25th and 75th percentile) between initial diag-
nosis and time of inclusion in the study was 4 [2; 6] and
4 [3; 6] years for patients diagnosed with FSGS and MCD,
respectively. Furthermore, children with INS were divided
into two groups based on the urine specimen results inde-
pendently of the histopathological diagnosis: (1) patients in
remission (total n of patients in remission28: 21 MCD, 7
FSGS) and (2) patients in relapse (total n of patients in
relapse16: 14 MCD, 2 FSGS). Remission was defined as a
urinary protein over creatinine ratio of ≤20 g/mol or 0.2 g/g.
Relapse was defined as a measurement of ≥2+ on urinary
dipsticks for at least 3 consecutive days, as confirmed by a
urine protein/creatinine ratio of >200 g/mol or 2 g/g. Urinary
excretion of α1M, βNAG and NGAL were measured in all
groups. The INS patients’ demographic characteristics and
treatment are summarized in Table 1.
Analytical methods
Blood samples with lithium heparinate were processed imme-
diately for plasma creatinine determination, and spot urine
samples were analyzed immediately for creatinine, uNGAL,
uα1M and uβNAG determination. Serum creatinine (SCreat)
was measured on a Modular P system (Roche Diagnostics,
Indianapolis, IN) using the kinetic colorimetric compensated
Jaffe method fromRoche Diagnostics. Inter-assay coefficients
of variation obtained with the internal quality controls were
3.9 % at 46 μmol/l and 2.4 % at 108 μmol/l. Urine creatinine
(uCreat) was determined using the same method but was
calibrated in on a homemade aqueous creatinine solution of
15.1 mmol/l. Inter-assay CVs were 1.7 % at 7.2 mmol/l and
0.7 % at 12.8 mmol/l. uβNAG was measured with a colori-
metric assay using sodium-3-cresolsulfonphthaleinyl-N-
acetyl-β-D-glucosaminide as substrate (Roche Applied
Science, Rotkreuz, Switzerland) adapted on a Modular P and
calibrated with the uβNAG standard from Roche Applied
Science. Inter-assay CVs were 1.2 % at 9 U/l and 0.9 % at
90 U/l. uNGAL was determined by a chemiluminescent
microparticule immunoassay on an Architect i1000SR
(Abbott Diagnostics, North Chicago, IL). During the entire
study, inter-assay CVs determined on the three levels of
internal quality controls were ≤2.2 % (respective means of
controls: 21, 184 and 1,196 μg/l). uα1M was measured by
immunonephelometry on a BN ProSpec analyzer (Siemens
Healthcare Diagnostics, Tarrytown, NY) with an inter-assay
CVof 5.3 % at 37.7 mg/l.
GFR estimation methods
The estimated GFR (eGFR) was calculated using the revised
Schwartz and the new Quadratic formulas as follows:
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& Revised Schwartz formula [9]:
eGFR ¼ 0:413 Height
.
SCreat
 
& Quadratic formula [10]:
– Males:
eGFR ¼ 0:68 Height
.
SCreat
 
−0:0008
 Height
.
SCreat
 2
þ 0:48 age−21:53
– Females:
eGFR ¼ 0:68 Height
.
SCreat
 
−0:0008
 Height
.
SCreat
 2
þ 0:48 age–25:68
In all formulas, height is in centimeters, SCreat is in milligrams
per deciliter, eGFR is in milliliter per minute per 1.73 m2
Histological evaluation of the renal biopsies
Renal tissue was obtained by percutaneous biopsy in 44
children diagnosed with INS. All specimens were fixed in
Bouin’s alcoholic solution, post-fixed in formalin and then
embedded in Paraffin. Sections were cut at a thickness of
2–3 μm and stained routinely with hematoxylin and eosin,
periodic acid-Schiff and periodic acid-silver-methenamine.
All biopsy sections were examined by electron microscopy.
Statistical analysis
Collected data were analyzed using R software, version 2.13.1
(R Foundation for Statistical Computing, Vienna, Austria;
www.R-project.org). Data were reported as medians with upper
and lower quartiles for continuous parameters (IQR; 25th; 75th
percentile), and categorical variables are expressed as percent-
ages. The bilateral Fisher exact test was used for the comparison
of nominal variables. For continuous variables, the difference
was computed with the Mann–Whitney U test or the t test
according to the number and normality of the data. Thus, for
the comparisons between MCD and FSGS groups we used the
Mann–Whitney U test, whereas the t test was used to compare
the log-transformed uNGAL/uCreat ratio values between the
control group and the pooled MCD and FSGS groups.
Prognostic accuracies were assessed by receiver operating char-
acteristic (ROC) curve analyses providing the area under the
curve (AUC) and 95 % confidence intervals using a nonpara-
metric approach as proposed by Delong [11]. Finally, correla-
tion analysis of uα1M, uβNAG and uNGAL with the urinary
protein excretion indexed to urinary creatinine was assessed
using the Spearman rank correlation test, and linear regression
analysis was performed using the logarithmic value of these
Table 1 Descriptive demographics
All patients MCD FSGS p valuea Children in
relapse
Children in
remission
p valuea
n 44 35 9 - 13 31 -
Median age (year) 10 [5; 13] 10 [5.2; 12] 13 [5; 16] 0.41 9 [4.7; 11.5] 10 [5.5; 13] 0.32
Median weight (Kg) 38.7 [29.1; 56.5] 36 [30; 53] 51 [29; 69.7] 0.58 33.5 [23.3; 59.2] 40.5 [31; 53.2] 0.68
Median height (cm) 145 [126; 159] 145 [131; 159] 152 [122; 159] 0.87 138 [120; 161] 147 [134; 158] 0.47
Median uNGAL (μg/l) 4.6 [1.98; 12] 2.7 [1.9; 8.3] 12.1 [7.1; 45.4] 0.01 3.5 [1.7; 9.4] 4.6 [2.1; 12.0] 0.68
Median uβNAG (U/l) 5.9 [4; 8.93] 5.9 [4.0; 10.2] 5.9 [4.0; 8.1] 0.86 11.5 [7.3; 18.9] 4.0 [4.0; 5.9] 0.001
Median uα1M (mg/l) 2 [0.88; 4.72] 1.7 [0.8; 5.0] 2.6 [1.6; 4.1] 0.35 6.8 [2.5; 12.7] 1.6 [0.8; 2.6] 0.002
Median uNGAL/uCreat (μg/mmol) 1.24 [0.58; 5.29] 1.0 [0.5; 1.8] 8.3 [2.1; 27.4] 0.02 1.5 [0.6; 1.9] 1.1 [0.6; 7.2] 0.76
Median uβNAG/uCreat (U/mmol) 2.24 [1.18; 6.8] 2.1 [1.1; 5.9] 4.8 [1.4; 9.9] 0.38 3.1[1.7; 6.8] 1.8 [0.9; 5.7] 0.31
Median uα1M /uCreat (mg/mmol) 0.3 [0.2; 0.73] 0.3 [0.2; 0.8] 0.3 [0.3; 0.6] 0.68 1.6 [0.5; 2.9] 0.2 [0.2; 0.3] 0.001
Median eGFR using Schwartz formula 112 [94; 134] 113 [95; 138] 109 [80; 124] 0.20 114 [94; 140] 111 [94; 129] 0.69
Median eGFR using Quadratic formula 108 [98; 116] 108 [98; 116] 106 [98; 111] 0.56 108 [98; 117] 109 [98; 114] 0.75
Number of children under steroid
treatment
31 26 5 - 9 22 -
Number of children under cyclosporine
treatment
13 6 7 - 3 10 -
Number of children under CellCept
treatment
12 8 4 - 1 11 -
MCD, minimal change disease; FSGS, focal segmental glomerulosclerosis; uNGAL, urinary Neutrophil-gelatinase-associated lipocalin; uβNAG,
urinary N-Acetyl-Beta-D-glucosaminidase; uα1M, urinary alpha1-microglobulin; uCreat, urinary creatinine; eGFR, estimated glomerular filtration
rate expressed in ml/mn per 1.73m2 . Continuous parameters are presented as the median with the interquartile range (IQR; 25 %; 75 % as lower and
upper quartiles) given in square brackets. a p values were obtained using the Wilcoxon-Mann–Whitney test.
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three parameters to support visual inspections. Statistical sig-
nificance was assessed at the 0.05 level for all analyses.
Results
uNGAL excretion in INS
uNGAL excretion in children with MCD and FSGS
The median [IQR] uNGAL concentration was significantly
(p=0.01) higher in patients with FSGS than in patients with
MCD (12.1 [7.1; 45.4] vs. 2.7 [1.9; 8.3] μg/l, respectively).
The results remained unchanged when uNGAL was indexed
to uCreat (8.3 [2.1; 27.4] vs. 1.0 [0.5; 1.8] μg/mmol, respec-
tively; p=0.02). In addition, uNGAL, indexed or not to
uCreat, was also significantly different between INS and
healthy children (p=0.02) and between healthy and children
with FSGS (p=0.007). The AUC for the uNGAL/uCreat ratio
as a biomarker to distinguish FSGS from MCD was 0.76
[0.57; 0.95] (p = 0.01) and showed an optimized sensitivity
of 0.77 and specificity of 0.78 with an optimal cut-off value,
calculated according to Youden et al. [12], of 1.93 μg/mmol
(corresponding to 17 ng/mg) (Fig. 1a).
Correlation between uNGAL excretion and proteinuria level
The correlation between uNGAL indexed or not to the
uCreat and the protein excretion related to uCreat in the
whole study group with INS was close to 0 (Spearman
correlation coefficient r −0.05 and −0.04 with p values of
0.75 and 0.81, respectively) (Fig. 2a) and was also observed
in MCD and FSGS patients. This latter observation demon-
strated that the higher uNGAL values in FSGS, which en-
abled this group to be distinguished from the MCD group,
were not related to a higher urinary protein/creatinine ratio.
There was also no significant difference in median uNGAL
indexed to the uCreat between patients in relapse versus
those in remission (p=0.76) (Fig. 3a).
Fig. 1 Receiver operator
characteristic curves (ROC) for
urinary neutrophil gelatinase-
associated lipocalin (uNGAL)
(a), urinary alpha 1-
microglobulin (uα1M) (b) and
urinary N-acetyl-beta-D-
glucosaminidase (uβNAG) (c)
for differentiating minimal
change disease (MCD) from
focal segmental
glomerulosclerosis (FSGS).
uNGAL was found to have
significant power to distinguish
MCD from FSGS with an area
under the curve (AUC) of 0.76
(interquartile range [0.57; 0.95])
(p=0.01)
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Correlation between uNGAL excretion and eGFR
For the each patient group, there was no significant correlation
between uNGAL and the uNGAL indexed to the uCreat and
the eGFR (p = 0.26 and 0.45, respectively, with the revised
Schwartz formula, and p = 0.57 and 0.48, respectively, with
the new Quadratic formula). Sub-analysis for the FSGS and
MCD groups also showed no significant correlation between
eGFR and uNGAL excretion. In addition, using a multivariate
analysis in which eGFR was a controlling co-variate, we
found that uNGAL distinguished between FSGS and MCD
and that this difference was independent of GFR levels. These
results indicated that the highest uNGAL levels obtained in
our FSGS patients were not related to renal disease severity.
uα1M excretion in INS
uα1M excretion in children with MCD and FSGS
The median [IQR] uα1M concentration in FSGS patients
was not significantly different (p=0.35) from that in MCD
patients (2.6 [1.6; 4.1] vs. 1.7 [0.8; 5] mg/l, respectively).
uα1M indexed to uCreat was also not significantly different
between FSGS and MCD patients (0.3 [0.3; 0.6] vs. 0.3 [0.2;
0.8] mg/mmol, respectively). The AUC for the uα1M as a
tool to distinguish MCD from FSGS was 0.52 [0.32; 0.71]
(Fig. 1b); this value was not significant (p = 0.86). These
results remained unchanged when uα1M was indexed to
uCreat (AUC 0.60 [0.37; 0.82]; not significant p = 0.38).
Correlation between uα1M excretion and proteinuria level
For the whole group with INS, the correlation between the
uα1M related to the uCreat and the protein excretion
corrected for uCreat showed a positive and significant cor-
relation coefficient (r=0.79, p<0.001) (Fig. 2b). In addition,
median uα1M related or not to the uCreat for patients in
relapse was significantly higher than that for those children
in remission (p=0.001) (Fig. 2c), independently of the his-
topathological diagnosis.
Correlation between uα1M excretion and eGFR
The correlation between the uβNAG and the eGFR using the
revised Schwartz and the new Quadratic formulas was poor
and not significant (r=0.28 and 0.24, p=0.067 and 0.129,
respectively), with no differences between the FSGS and
MCD groups.
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bFig. 2 Scattergraph depicting
the relationships of the
logarithms of urinary neutrophil
gelatinase-associated lipocalin
(uNGAL) to urinary creatinine
(uCreat) ratio (a), uα1M to
uCreat ratio (b) and uβNAG to
uCreat ratio (c) with the
logarithms of the urinary protein
(uProt) to uCreat (uProt/uCreat)
ratio in minimal change disease
(MCD) patients (dotted lines)
and focal seymental
glomerulosclerosis (FSGS)
(dashed lines). The correlation
coefficients are: r=−0.05,
p=0.75 (uNGAL), r=0.79,
p<0.001 (uα1M) and r=0.12,
p=0.38 (uβNAG)
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uβNAG excretion in INS
uβNAG excretion in children with MCD and FSGS
The median [IQR] uβNAG concentration in FSGS patients
was not significantly different (p=0.86) from that in MCD
patients (5.9 [4.0; 8.1] vs. 5.9 [4.0;10.2] U/l, respectively).
uβNAG indexed to uCreat also did not significantly differ
between the FSGS and MCD groups (4.8 [1.4; 9.9] vs. 2.1
[1.1; 5.9] U/mmol, respectively). The AUC for uβNAG to
distinguish MCD from FSGS was 0.60 [0.42; 0.78] (Fig. 1c)
(not significant p = 0.35). These results remained unchanged
when uβNAG was indexed to uCreat (AUC 0.54 [0.34;
0.75]; not significant p = 0.68).
Correlation between uβNAG excretion and proteinuria level
The correlation between uβNAG and the protein excretion
corrected to uCreat was very low and not significant
(r=0.12, p=0.38) (Fig. 2c). On the other hand, there was
no significant difference in median uβNAG indexed to the
uCreat between patients in relapse versus those in remission
(p=0.31) (Fig. 3c).
Correlation between uβNAG excretion and eGFR
The correlation between the uβNAG and the eGFR using the
revised Schwartz and the new Quadratic formulas was poor
and not significant (r=0.25 and 0.24; p=0.106 and 0.120,
respectively), again with no differences between the FSGS
and MCD groups.
Discussion
Several tubular urinary markers have been studied in INS
with conflicting results. Sesso et al. [6] showed that urinary
RBP and β2M levels may be helpful biomarkers for
distinguishing established SRINS from SSINS. Caliskan
et al. [8] and Valles et al. [13] showed no difference in the
urinary β2M excretion in children who are more likely to be
responsive to steroid treatments. During the past few years,
Fig. 3 Box plot for the median
uNGAL to uCreat ratio (a),
median uα1M to uCreat ratio (b)
andmedian urinaryN-Acetyl-beta-
D-glucosaminidase (uβNAG) to
urinary creatinine (uCreat) ratio (c)
for differentiating idiopathic ne-
phrotic syndrome (INS) patients in
remission (RE) from INS patients
in relapse (RL). The median
uα1M/uCreat ratio for patients in
RL was significantly higher than
that for those in RE (p<0.001)
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major efforts have been made to identify new urinary bio-
markers that would allow physicians to differentiate SRINS
from SSINS. Woroneicki et al. evaluated various urinary
proteomic markers [14] and urinary cytokine panels [15] to
identify whether any of these factors could distinguish
SRINS from SSINS, but the results were nonconclusive.
Bennett et al. [1] recently demonstrated that the ratio of
uNGAL to urinary creatinine could be used to differentiate
SSNS from SRNS; in addition, this new urinary biomarker
was correlated with disease severity in SRNS.
Our study cohort comprised children with biopsy-proven
established kidney disease. In this cohort, our results showed
that using a cut-off value of 17 ng/mg, the uNGAL/uCreat
ratio enabled MCD to be distinguished from FSGS with an
AUC of 0.75 (p=0.01) and an optimized sensitivity of 0.77
and specificity of 0.78. This finding has important implica-
tions in clinical practice as we have demonstrated the role of
uNGAL as a novel biomarker in children with INS, thereby
confirming the findings of Bennett et al. [1]. We also found
that uNGAL can readily distinguish between the two differ-
ent histopathological glomerular diseases, independent of
GFR or proteinuria levels.
The underlying pathophysiological mechanisms of
uNGAL excretion/metabolism in INS are still unknown.
Different hypotheses have been explored in previous inves-
tigations, such as an injured glomerular barrier, a possible
adaptive tubular response to injury by NGAL inhibition of
apoptosis or an abnormal cubulin–megalin transporter [16].
Regarding urinary LMWP excretion in children with INS
in remission or in relapse, we obtained discordant results.
There was a significant increase in the median uα1M/uCreat
ratio in children with relapse compared to those in remission.
This increase in the uα1M/uCreat ratio was significant and
positively related to the level of proteinuria (r=0.79).
However, the medians of the uNGAL/uCreat and
uβNAG/uCreat ratios were not significantly different be-
tween children in remission and children in relapse. The
observation of increasing uα1M concentration in relapsed
INS compared to the remission state is consistent with the
previously described hypothesis that proteinuria decreases
the absorption of LWMP through competition for common
transport mechanisms [17–20] but it also does not exclude
the association of proximal tubular injury related to intersti-
tial fibrosis from the underlying disease [21–23]. This prox-
imal tubular injury could also be secondary to tubular ische-
mia, as reported by Sesso et al. [6]. There is therefore a need
for studies on the measurement of cellular tubular oxygena-
tion during remissions and relapses to confirm or not the
Sesso hypothesis.
In brief, mechanisms of urinary excretion of LWMP in the
condition of relapsed INS are still not well established and
may be secondary to several tubular pathophysiological pro-
cesses. A delicate and complicated interplay, as yet not
completely resolved, between uNGAL, the glomerular fil-
tration process; proximal tubular reabsorption and distal
tubular secretion might explain the lack of difference be-
tween uNGAL concentration in children with INS in relapse
and in remission.
There are a number of limitations to this study. First, the
majority of children with FSGS were already on calcineurin
inhibitor (CNI) treatment at the date of inclusion. Several
studies showed contrasting results regarding the impact of
CNI on uNGAL excretion in children with INS [1, 24]. The
number of children included was fairly small, especially in
the FSGS group, and therefore, the impact of CNI could not
be evaluated in our study group. Secondly, although we
found a uNGAL cut-off with good sensitivity and specificity,
additional larger studies are needed to validate this new
urinary cut-off as a potential alternative marker that could
replace renal biopsy. Finally, given the fact that all our FSGS
patients had histological lesions not otherwise specified, we
could not assess the role of FSGS subtypes on uNGAL
excretion.
To our knowledge, this study is the first to demonstrate
that uNGAL can distinguish children with biopsy-proven
MCD from those with FSGS In addition, we provide a
urinary NGAL to creatinine ratio cut-off point that can be
helpful in clinical practice to differentiate these two histo-
pathological diagnoses.
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